Noven’s Product Development capabilities and expertise extend from product formulation to product approval and beyond. Our capabilities include in-house product formulation, development, clinical testing, and regulatory and medical affairs. In its history, Noven has received FDA approval for eight products, and currently has applications for two developmental products pending.
Noven is also working collaboratively with its parent company, Hisamitsu, to develop new prescription transdermal systems, and potentially new transdermal technologies that could extend the number of compounds that can be delivered through the skin, bringing the benefits of patch therapy to patients around the world.
The following table summarizes the status of products marketed, approved, and/or under development by Noven. Developmental products are identified in yellow.
|Noven Therapeutics Central Nervous System|
|Daytrana® (methylphenidate transdermal system)||ADHD in children 6-17 years old||Marketed in U.S.||Noven|
|Noven Therapeutics Women's Health|
(estradiol transdermal system)
|Moderate to severe vasomotor symptoms and prevention of post-menopausal osteoporosis||Marketed in U.S.||Noven|
(estradiol / NETA transdermal system)
|Moderate to severe vasomotor symptoms; moderate to severe vulvar and vaginal atrophy; treatment of hypoestrogenism||Marketed in U.S.||Noven|
|Lidocaine Topical Patch (generic)||Pain associated with post herpetic neuralgia||Pending
|Rivastigimine Transdermal System (generic)||Mild to moderate dementia of the Alzheimer's type; Mild to moderate dementia associated with Parkinson's disease||Pending
|Parent Company Collaboration|
|Multiple Undisclosed Projects||Various||Pre-clinical and clinical development||Hisamitsu/Noven|